Locally advanced research hub

A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

This study is testing a new combination of drugs, ociperlimab and tislelizumab, against a standard treatment, pembrolizumab, for a serious type of lung cancer. The aim is to see if the new combination can help people live longer and improve their quality of life.